drugset / Trial / NCT03002428

A Comparison of PF708 and Forteo in Osteoporosis Patients

NCT03002428

Phase 3 Completed 181 enrolled Pfenex, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effects of two teriparatide products, PF708 and Forteo, in patients with osteoporosis.

Timeline

Start
2016-12
Primary completion
2018-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications